Table 1.
Characteristics of users and non-users of any antidepressants after a diagnosis of breast cancer and before recurrence (Group Health, 1990–2008), N=4,216
| All | Any antidepressant use after diagnosis | ||
|---|---|---|---|
| No | Yes | ||
| (N=4216) n (%)a |
(N=1914) n (%)a |
(N=2302) n (%)a |
|
| Age at diagnosis (years) | |||
| Mean (SD) | 62.2 (13.3) | 62.5 (13.2) | 62.6 (13.4) |
| 18–39 | 139 (3.3) | 65 (3.4) | 74 (3.2) |
| 40–49 | 646 (15.3) | 285 (14.9) | 361 (15.7) |
| 50–59 | 995 (23.6) | 438 (22.9) | 557 (24.2) |
| 60–69 | 1018 (24.1) | 491 (25.7) | 527 (22.9) |
| 70–79 | 940 (22.3) | 436 (22.8) | 504 (21.9) |
| ≥80 | 478 (11.3) | 199 (10.4) | 279 (12.1) |
| Year of diagnosis | |||
| 1990–1994 | 950 (22.5) | 442 (23.1) | 508 (22.1) |
| 1995–1999 | 1191 (28.2) | 520 (27.2) | 671 (29.1) |
| 2000–2004 | 1201 (28.5) | 513 (26.8) | 688 (29.9) |
| 2005–2008 | 874 (20.7) | 439 (22.9) | 435 (18.9) |
| Follow-up time | |||
| Mean (SD) | 7.1 (4.3) | 6.6 (4.3) | 7.4 (4.3) |
| Median | 6.3 | 5.7 | 6.7 |
| Race | |||
| White | 3719 (88.5) | 1640 (86.1) | 2079 (90.5) |
| African American | 136 (3.2) | 73 (3.8) | 63 (2.7) |
| American Indian/Alaska Native | 113 (2.7) | 44 (2.3) | 69 (2.7) |
| Asian/Pacific Islander | 233 (5.5) | 148 (7.8) | 85 (3.7) |
| Other | 1 (0) | 0 (0) | 1 (0) |
| Unknown | 14 | 9 | 5 |
| Ethnicity | |||
| Not Hispanic | 3976 (94.6) | 1798 (94.2) | 2178 (94.8) |
| Hispanic | 229 (5.4) | 110 (5.8) | 119 (5.2) |
| Unknown | 11 | 6 | 5 |
| Menopausal status at diagnosis | |||
| Peri- or Premenopausal | 1145 (27.2) | 522 (27.3) | 623 (27.1) |
| Postmenopausal | 3071 (72.8) | 1392 (72.7) | 1679 (72.9) |
| Education | |||
| High school or less | 418 (23.4) | 188 (22.1) | 230 (24.5) |
| Some college | 634 (35.4) | 281 (33.0) | 353 (37.6) |
| College or post graduate | 737 (41.2) | 382 (44.9) | 355 (37.8) |
| Unknown | 2427 | 1063 | 1364 |
| Cancer characteristics | |||
| AJCC stage at diagnosis | |||
| I | 2648 (62.8) | 1175 (61.4) | 1473 (64.0) |
| IIA | 1078 (25.6) | 518 (27.1) | 560 (24.3) |
| IIB | 490 (11.6) | 221 (11.5) | 269 (11.7) |
| Lymph node status | |||
| Unknown | 451 | 195 | 256 |
| Negative | 2847 (75.6) | 1304 (75.9) | 1543 (75.4) |
| Positive (1–3 nodes) | 680 (18.1) | 309 (18) | 371 (18.1) |
| Positive (≥4 nodes) | 234 (6.2) | 104 (6.1) | 130 (6.4) |
| Positive (unknown number of nodes) | 4 (0.1) | 2 (0.1) | 2 (0.1) |
| Tumor size | |||
| <2.0 cm | 3110 (73.8) | 1392 (72.8) | 1718 (74.7) |
| ≥2.0 cm | 1104 (26.2) | 521 (27.2) | 583 (25.3) |
| Unknown | 2 | 1 | 1 |
| Tumor histology | |||
| Ductal | 3315 (78.6) | 1506 (78.7) | 1809 (78.6) |
| Lobular | 336 (8) | 147 (7.7) | 189 (8.2) |
| Mixed/other | 565 (13.4) | 261 (13.7) | 304 (13.3) |
| Tumor grade | |||
| Well differentiated | 1041 (26.9) | 471 (26.7) | 570 (27.1) |
| Moderately differentiated | 1600 (41.3) | 714 (40.4) | 886 (42.1) |
| Poorly/undifferentiated | 1233 (31.9) | 582 (33.0) | 651 (30.9) |
| Not determined or stated | 342 | 147 | 195 |
| ER/PR status | |||
| ER & PR unknown | 217 | 93 | 124 |
| ER−/PR− | 667 (16.7) | 313 (17.2) | 354 (16.3) |
| ER+/PR− | 383 (9.6) | 177 (9.7) | 206 (9.5) |
| ER−/PR+ | 61 (1.5) | 24 (1.3) | 37 (1.7) |
| ER+/PR+ | 2888 (72.2) | 1307 (71.8) | 1581 (72.6) |
| Her-2 test (diagnosis in 1998+ only) | |||
| Test done | 2074 (79.7) | 950 (81.0) | 1124 (78.7) |
| Her-2 test result among women with test done | |||
| Positive/Borderline | 353 (17.0) | 152 (16.0) | 201 (17.9) |
| Negative | 1714 (82.6) | 795 (83.7) | 919 (81.8) |
| No result | 7 (0.3) | 3 (0.3) | 4 (0.4) |
| Cancer treatment | |||
| Primary therapy | |||
| Mastectomy with or without radiation | 1521 (36.1) | 635 (33.2) | 886 (38.5) |
| Breast conserving surgery with radiation | 2172 (51.5) | 1039 (54.3) | 1133 (49.2) |
| Breast conserving surgery without radiation | 523 (12.4) | 240 (12.5) | 283 (12.3) |
| Adjuvant treatment (not mutually exclusive) | |||
| Chemotherapy | 1376 (32.6) | 586 (30.6) | 790 (34.3) |
| Tamoxifen | 2057 (48.8) | 884 (46.2) | 1173 (51.0) |
| Aromatase Inhibitor | 849 (20.1) | 353 (18.4) | 496 (21.6) |
| Health history in year prior to diagnosis | |||
| Charlson Index | |||
| 0 | 3229 (76.6) | 1541 (80.5) | 1688 (73.3) |
| 1 | 704 (16.7) | 263 (13.7) | 441 (19.2) |
| ≥2 | 283 (6.7) | 110 (5.7) | 173 (7.5) |
| Body mass index (kg/m2) | |||
| <18.5 | 69 (1.6) | 29 (1.5) | 40 (1.7) |
| 18.5 to <25 kg/m2 | 1453 (34.6) | 698 (36.6) | 755 (33.0) |
| 25 to <30 kg/m2 | 1362 (32.5) | 636 (33.4) | 726 (31.7) |
| 30 to <35 kg/m2 | 766 (18.3) | 330 (17.3) | 436 (19.0) |
| ≥35 kg/m2 | 546 (13.0) | 212 (11.1) | 334 (14.6) |
| Unknown | 20 | 9 | 11 |
| Smoking status | |||
| Current | 253 (6.0) | 83 (4.3) | 170 (7.4) |
| Past | 352 (8.3) | 169 (8.8) | 183 (7.9) |
| Never/Unknown | 3611 (85.6) | 1662 (86.8) | 1949 (84.7) |
| Diagnosis of depression | 402 (9.5) | 39 (2.0) | 363 (15.8) |
| Diagnosis of anxiety | 174 (4.1) | 30 (1.6) | 144 (6.3) |
| Mental health diagnosis | 795 (21.7) | 166 (10.1) | 629 (31.1) |
| Antidepressant use | 935 (22.2) | 53 (2.8) | 882 (38.3) |
| SSRIs | 452 (10.7) | 17 (0.9) | 435 (18.9) |
| TCAs | 422 (10.0) | 28 (1.5) | 394 (17.1) |
| Miscellaneous | 280 (6.6) | 12 (0.6) | 268 (11.6) |
AJCC = American Joint Committee on Cancer; ER = estrogen receptor; PR = progesterone receptor; SD = standard deviation; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant
a
Column percents may not add to 100% due to rounding